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ABSTRACT
The ethics of placebo research have been of paramount concern since the discovery of the phenomenon.
To address these ethical concerns, Miller and colleagues (PLoS Med 2005 Sep;2(9):e262, 0853-0859) pro-
pose an altemate approach to placebo research, called "authorized deception", in which participants are
alerted of the use of deception in the research prior to study enrollment and thus knowingly permit its
use if they decide to participate. The present study sought to investigate the authorized deception meth-
odology in experimentally induced placebo analgesia. The participants were randomly assigned to an
authorized deception or non-authorized deception group. A commonly used protocol was employed
wherein heat pain stimulation was surreptitiously lowered following the application of a placebo cream
during a series of conditioning trials and the magnitude of the placebo effect was subsequently assessed
in test trials for which the stimulus intensity was the same for both the placebo and control creams.
Authorized deception did not have any negative impact on the magnitude ofthe placebo effect, recruit-
ment and retention of participants, nor did it result in any significant psychological harm. The majority of
participants who received this form of consent preferred it to the traditional approach in which the par-
ticipants are not alerted to the presence of deception. These findings suggest that the use of authorized
deception is a viable and ethically preferable alternative consent process for laboratory-based studies on
placebo analgesia. Further studies are needed to examine the effect of authorized deception in clinical
trials and other placebo research within a clinical setting.
1. Introduction
Placebos have the potential to enhance the therapeutic outcome
of medical interventions and are a source of important variability
to be considered in clinical trials designed to evaluate treatment
efficacy [14]. However, the methodology by which placebo effects
are investigated has raised some ethical concerns [5,10,14,151. Be-
cause placebo analgesia is strongly influenced by the recipient's
expectations [16-18], clinical and experimental studies typically
rely on the use ofdeception regarding the purpose ofthe research
and/or the nature of the treatment being administered, thereby
leading the participants to believe that they are receiving a physi-
cally active treatment when in fact they are receiving a placebo
[14]. This use ofdeception is oftenjustified on the grounds that full
disclosure about the purpose of the research or the experimental
procedures may influence the participants' responses and thus
jeopardize scientific knowledge [14]. As such, deception is often
seen as a necessary means of promoting the internal and external
validities of placebo research [13].
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However, as Miller and colleagues [13,15] highlight, use of
deception conflicts with ethical principles of human experimenta-
tion as it: (1 ) violates the principle of respect for persons by failing
to disclose relevant information that might affect an individual's
decision to volunteer for a research study; (2) may manipulate
individuals to participate in research that they would not have;
and (3) may cause distress and lack of trust in research when the
deception is revealed. Furthermore, the American Pain Society po-
sition statement on the use of placebos in clinical pain manage-
ment highlights, "deception of patients about clinical treatments
violates the right of patients to consent to or refuse treatment"
([22] p.216).
Miller and colleagues 114,15,261advocate an alternate approach
to the consent process in deceptive research. The participants are
informed, prior to deciding whether to participate in a study that
some features of the study will or may be misleading or deceptive.
They call this form of consent "authorized deception", since the
participants are alerted to the presence of deception in the re-
search and thus knowingly permit its use if they decide to partic-
ipate [15]. Additionally, the participants may be offered the
opportunity to withdraw their data after they have been informed
about the true nature of the study as a means of restoring partici-
pant autonomy [14].
Criticisms of the authorized deception approach are that it may
create suspicion, thus resulting in biased data [15], reduce partici-
pant enrollment [2,15] and/or cause anxiety [4]. Providing partici-
pants the opportunity to withdraw their data also may limit the
generalizability of research findings [26] and introduce a participa-
tion bias.
The present study was designed to provide an evidence-based
evaluation of the authorized deception methodology in
experimentally induced placebo analgesia. The participants were
randomly assigned to an authorized deception group or a non-
authorized deception group. Key outcome variables included
assessment of differences in participant enrollment, magnitude of
the placebo effect, mood, satisfaction with the research experience,
attitudes toward researchers, beliefs regarding respect/infringe-
ment of individual rights, and willingness to participate in future
research ofthis kind.
2. Methods
2.1. Participants
Participants comprised 40 adults (28 females and 12 males;
mean age=21.78, SD=3.34 yrs) recruited from flyers posted
around the University campus, Prospective participants underwent
an initial telephone screen to rule out any medical conditions or
medication use that might interfere with pain sensitiviqr or in-
crease risk of unnecessary discomfort during thermal sensory test-
ing. Individuals were excluded if they reported an ongoing pain
problem, high blood pressure, circulatory problems, diabetes, heart
disease, asthma, seizures, frostbite, past trauma to the hands or
arms, lupus, other large or small joint disease or injury, or use of
analgesics, anti-inflammatory medications, psychoactive drugs
andior antihistamines. The York University Research Ethics Board
reviewed and approved the study protocol. The participants re-
ceived $20 for their involvement in the studv.
2.2. Apparatus
2.2. 1. Experimental setttng
The experiment took place on campus in a room set up with
medical equipment to resemble a physician's office including an
examination table, privacy curtain, medical scale for measuring
height and weight, blood pressure cuff, metal equipment tray, con-
tainers of cotton balls, tongue depressors, plastic syringes, rubbing
alcohol, and wall posters depicting the musculoskeletal system,
symptoms of neuropathic pain and the pathophysiology and anat-
omy of arthritis and knee injury.
2.2.2. Medoc thermal sensory analyzer
Heat pain was induced by means of a Medoc TSA-ll thermal
stimulator (Ramat Yishai, Israel). The TSA-ll is a computerized de-
vice designed to measure sensory thresholds to vibration and tem-
perature (e.g., warm, cold, heat-induced pain and cold-induced
pain). The TSAII is used in a variety of clinical disorders (e.g., dia-
betes, peripheral neuropathy) to obtain a quantitative evaluation
of the integrity of both small (A-delta and C) and large diameter
(A-beta) sensory nerve fibers. The TSA-ll is capable of delivering
thermal stimuli that range from approximately 0'C to 50 "C. A
thermode is attached to the participant's skin with a Velcro strap
and heat stimuli of various temperatures are administered. A par-
ticipant-initiated button press stops the rise in temperature and
the thermode rapidly returns to room temperature at a rate of
-4 "Cls. In the present study, thermal stimuli of 5 s duration were
applied to the skin through a thermode with a contact area 3 cm2.
The temperature of the thermode rose rapidly (4'C/s) from a base-
line temperature of 35 "C to a pre-programmed peak temperature
where it remained for 5 s before returning to baseline.
2.2.3. Placebo cream
The same over-the-counter hypoallergenic moisturizer cream
(Glaxal Base), which does not contain an active analgesic agent,
was used for both the placebo cream and the control cream. The
creams were visiblejn two plastic syringes on a metal medical tray
with the labels 'AlevocaineM and 'Control Cream'. The experi-
menter wore latex gloves while handling, applying, and removing
the creams. The creams were removed with an alcohol swab.
2.3. Response measures
2.3.1. Numeic rating scale (NRS) 
- 
pain
The participants were asked to rate the intensity of pain stimuli
using an 11-point, self-report, numeric rating scale (NRS) [7] rang-
ing from 0 to 10, with endpoints representingno pain (0) and fhe
most intense pain imaginable (10). The participants were asked to
choose the number that best corresponded to the intensity of each
heat pain stimulus they received. The NRS provides a simple, effi-
cient and minimally intrusive measure of pain intensity. This scale
is commonly used in clinical settings [1] and is the preferred pain
rating scale among patients a271. The NRS is highly correlated(r = 0.94) with the visual analog scale [1] and is sensitive to change
following pharmacological interventions [71.
2.3.2. Profile of mood states (POMS)
The profile of mood states (POMS) [12] is a widety used, 65-item
self-report scale designed to measure affective mood states and
their fluctuations in medical patients, psychiatric outpatients, nor-
mal adults, and college students. Each item is rated on a 5-point
scale ranging from nof at aU (0) to extremely (4). The right now rat-
ing period was used for the present study. The POMS yields a total
mood disturbance (TMD) score and 6-factor analytic-derived scales
including; (1) tension-anxiety, (2) depression-dejection, (3) an-
ger-hostility, (4) vigor-activiff, (5) fatigue-inerria, and (6) confu-
sion-bewilderment. The POMS has excellent intemal consistency
(a=0.84-0.95) and fair test-retest reliability (r=0.43-0.53) over
a 6-week period in patients receiving psychiatric treatment [11].
Evidence ofthe predictive and construct validity ofthe pOMS has
been demonstrated in brief psychotherapy research, cancer re-
search, controlled outpatient drug trails, studies on sports and ath-
letes, and studies of response to emotion-inducing conditions in
healthy populations [1 1 ].
2.3.3. Numeric rating scale (NRS) 
- 
attitudes
A numeric rating scale (ranging from 0 to 10) was used to assess
participants' attitudes across four domains: (1) satisfaction with
the research experience, (2) teelings toward researchers who plan
and run studies such as the present one, (3) the extent to which
they felt that their individual rights were respecred while taking
part in the study, and (4) their willingness to participate in similar
research in the future.
2.4. Procedure
The participants were randomly assigned to one of two groups
using the randomization program available at www.randomiza-
tion.com: authorized deception group or non-authorized deception
group. An experimenter wearing a white lab coat greeted the par-
ticipants upon arrival for the study. The participants were provided
with a consent form, and the experimenter verbally described the
study following a standard script, The participants in both groups
were told that the investigators were examining the effectiveness
of a new topical anesthetic cream called AlevocainerM which had
been shown to reduce pain in some individuals; and that the AIev-
ocaineru cream would be compared against a regular moisturizer
cream. The details of the thermal stimulator and the method of
assessing the effectiveness ofthe cream by means ofpainful heat
stimuli were described and the participants were told that they
could discontinue participation in the study at any time without
negative consequences.
The authorized deception group and the non-authorized decep-
tion group received identical information in the consent form with
the exception of one paragraph added to the end of the consent
form for the authorized deception group. In this paragraph, pro-
spective participants were informed, prior to deciding whether to
volunteer for the study, that some aspects of the study were being
intentionally misdescribed. Specifically, the following statement,
recommended by Miller et al. [15], was included at the end of
the consent form for the authorized deception group:
"You should be aware that the investigators have intentionally
misdescribed certain aspects of the study. This use of deception
is necessary to obtain valid results. However, an independent
ethics committee has determined that this consent form accu-
rately describes the major risk or benefits of the study. The
investigators will explain the misdescribed aspects of the study
to you at the end ofyour participation" (p.856).
The experimenter also repeated this statement verbally when
reviewing the study procedures with the participant to ensure that
all participants in the authorized deception group were aware of
this information.
Following the consent procedures, the participants in both the
authorized deception and non-authorized deception groups com-
pleted the POMS and a demographic and pain history question-
naire. The participants were then brought into a laboratory room
set-up to resemble a physician's office and underwent four consec-
utive stages of thermal sensory testing involving a set of familiar-
ization trials, calibration trials, conditioning trials, and test trials
[1s].
2.4. 1. Familiarization trials
In order to familiarize participants with the range of tempera-
tures, one trial each of 44,45',47", and 49'C stimuli was deliv-
ered in ascending order on the ventral side of the participant's
right forearm.
2.4.2. Calibrstion trials
The participants then underwent a series of calibration trials
similar to that of Price and colleagues [19] to control for individual
differences in pain perception. A series of 16 thermal stimuli rang-
ing between M and 49'C was administered in a random order
and the participants were asked to rate the pain intensity of each
stimulus on a 0-10 NRS. At the end of the calibration trials. a
regression equation was calculated for each participant in order
to predict thermal intensity (temperature in "C) from verbal pain
intensity report (NRS pain ratings). This calculation was used to
determine the temperature corresponding to each individual's
NRS pain rating of 6 and 3, which varied among participants
depending on their own personal perception of pain. These two
stimulus levels (i.e., temperatures) were used in all subsequent tri-
als and were specific to each individual,
2.4.3. Conditioning trials
A plastic template was used to mark two squares on the ventral
side of the participant's right forearm. Two square adhesive
patches with the center cut out were applied to these tvvo areas
to demarcate the two locations on the arm where the creams were
Fig: f. (A) Plastic template used to mark two squares on the ventral side of the
participant's right forearm. (B) Adhesive patches used to demarcate the two
locations on the arm where the creams were applied,
applied (Fig. 1). In line with previous research l'17,23-251, a condi-
tioning procedure was used in which the intensity of heat pain
stimuli was surreptitiously lowered during conditioning trials for
the placebo cream (i.e., AlevocainerM cream). That is, in order to
create the impression of analgesic efficacy (i.e., pain relief) when
testing in the area of skin where the placebo cream was applied,
the temperature was surreptitiously lowered to a level correspond-
ing to the participant's NRS pain rating of 3. When testing in the
area of skin where the control cream was applied, the temperature
was administered at a level corresponding to the participant's NRS
pain rating of 6. The participants were asked to verbally rate the
intensity of each stimulus using the 0-10 NRS. One block of four
thermal stimuli was administered for each cream at each of the
two locations according to a randomized counterbalanced design,
such that each participant received eight conditioning trials for
each cream.
2.4.4. Test trials
Immediately following the conditioning trials, the participants
received one final test trial with each cream. The stimulus intensity
for the test trials was the same for both the placebo (AlevocainerM)
and the control creams. That is, for the test trial, the stimulus
intensity was raised to a temperature corresponding to a pain rat-
ing of 6 for the 'AlevocainerM' condition. The magnitude of the pla-
cebo analgesic effect was determined by comparing the test trial
pain ratings for the placebo versus the control cream.
2.5. Post-test interview and debriefing
Following the test trials and before the debriefing process, the
participants were asked a series of questions about their feelings
concerning the research procedures they had just undergone and
their thoughts about the Alevocaineru cream. The participants in
the authorized deception group were asked to describe how they
had felt when they read in the consent form that cer{ain aspects
of the study were being intentionally misdescribed and that the
use of deception was necessary to obtain valid results. They were
also asked ifthey wondered what aspect(s) ofthe study had been
misdescribed and if so, what these aspects might have been.
The participants in both the authorized deception and non-
authorized deception groups were asked "At any point during the
study: did you wonder if Alevocaineru had side effects that we
weren't telling you about; did you wonder if Alevocaineru was an-
other drug that we didn't tell you about; and, did you wonder if
Alevocaineru might not be a real drug?" If the participants an-
swered yes to any of these questions they were asked "When did
you start to wonder this?" "Did this thought make you feel more
anxious?" and "Did this thought influence your pain ratings during
the study? (And if so, how?)"
Following this set of questions, the participants were given a
debriefing form describing the true purpose of the study and the
nature ofthe placebo cream. In the debriefing form the participants
were also offered the opportunity to withdraw their data from the
study if they felt concerned or uncomfortable about the fact that
they had been intentionally deceived. When given the debriefing
form, the participants in the authorized deception group were told,
"As you are aware, there were certain aspects of this study that I
was not able to explain fully to you at the beginning of your partic-
ipation. I would like to give you a debriefing form now that will ex-
plain the purpose of the study and outline the aspects that I was
not able to tell you about at the beginning". The participants in
the non-authorized deception group were told, "There were as-
pects of this study that I was not able to explain fully to you at
the beginning of your participation. I would like to give you a
debriefing form now that will explain the purpose of the study
and outline the aspects that I was not able to tell you about at
the beginning".
Immediately after the participants finished reading the debrief-
ing forms they were asked to complete the POMS a second time to
assess any changes in mood following their participation in the
study and the debriefing procedures. A brief set of questions was
then administered to both groups to assess their attitudes about
the research experience (see Section 2.3.3). Additionally, the par-
ticipants in the authorized deception group were re-read the same
paragraph from the consent form alerting them to the presence of
deception in the study and were asked, "Having participated now,
would you rather not have been informed of this at the beginning
of the study?" The participants in the non-authorized deception
group were read this same paragraph and were asked, "Having par-
ticipated now, would you rather have been informed of this [i.e.,
alerted to the presence of deceptionl at the beginning of the
study?"
3. Results
3.1. Magninde of the placebo effect
The magnitude of the placebo effect for each group was calcu-
lated by subtracting the pain intensity rating for the placebo cream
from the pain intensity rating for the control cream during the final
trial (i.e., when the temperature was the same for both creams).
The resulting placebo response score represents the change in pain
Authorized Decegtion Non-Authorized D€cettion
Group
Fig;' 2. Mean pain ratings for the placebo (AlevocainerM) and control creams in the
authorized deception and non-authorized deception groups. Error bars represent
standard erors. Data indicate a significant placebo effect for each group. p < 0.001
comparing placebo (Alevocaineru) with control,
intensity rating due to the administration ofthe placebo [17]. Both
the authorized deception and the non-authorized deception groups
obtained positive scores averaging 1.05 (SD-1.43) and 1.40
(SD = 2.35), respectively, indicating a less painful response to the
placebo cream than to the control cream (i.e., a placebo effect).
In order to determine whether there was a difference in the
magnitude of the placebo effect between the authorized deception
group and the non-authorized deception group, a2 x2 between-
within analysis of variance (ANOVA) was conducted, using group
(authorized deception and non-authorized deception) as the be-
tween-subjects factor and cream (placebo and control) as the with-
in-subjects repeated measures factor. ANOVA results revealed a
non-significant group x cream interaction, F (1,38)=0.32,
p=O.57. The main effect of cream (Placebo/Control), F
(1,38)= 75.87,p < 0.001, indicated significantly lower pain ratings
for placebo (MtSD=5.1012.50) as compared to control cream
(MISD=6.3312.09) across both groups. The group effect was
not significant, F (1,38) =0.41, p < 0.53. Taken together, these re-
sults indicate that both groups showed a significant placebo effect,
the magnitude of which did not differ significantly between the
authorized deception and non-authorized deception groups
(Fie. 2).
3.2. Mood
Means and standard deviations for each of the POMS scales are
presented in Table 1. A series of between-within ANOVAs were
conducted on each of the following POMS scales using time
(post-consent vs. post-debrief) as the within-subjects factor and
group (authorized deception and non-authorized deception) as
the between-subjects factor: (1) tension-anxiety, (2) depression-
dejection (3) anger-hostility, (4) vigor-activiry, (5) fatigue-inertia,
(6) confusion-bewilderment, and (7) total mood disturbance. Nei-
ther the group main effect nor the group x time interaction effect
was significant for any of the mood scales. The time effect revealed
significant improvements from post-consent to post-debrief for all
the mood scales, with the exception of the vigor-activity scale,
which remained unchanged (Table 2). These results indicate signif-
icant improvements, independent of group, over time for tension-
anxiety, depression-dejection, anger-hostility, fatigue-inertia,
confusion-bewilderment, and total mood disturbance.
Table 1
Means and standard deviations of POMS scores for authorized deception and non-authorized deception groups at time 1 (post-consent) and time 2 (post-debriefing).
POMS scale Autharized deception group Non-authorized deception gtoup
Time 1 M (sD) Tirne 2 M (SD) Tirae l M(SD) Tjme 2 M (sD)
T=A-- -- .
D-D
A-H .
rH-
F=l
c-B
TMD
s.4s (3.68)
4.80 (7.58)
2rs (3.66)
1r.80 (6.99)
s.rs (4.ss)
s.65 (3.s7)
71.70 (22.18)
6;60{3.?6)
535(rc.Qs)
430 (S:9)
11.70 (5.93)
6.50 (s.46)
5.70 (3,63)
16J5 (30.24)
4.15 (2.08)
3.20{6.86)
2.00 (3.31)
11.15 (5.63)
4,45 (4.59)
3;95 (2.98)
6.60 (19.66)
4.Os (2.48\ - -
1.7 (3.88)
13s (2.37)
12.35 (10.92)--
3.50 (3.49)
3.75 t2.4o)
2.00 (18.17)
Nore: T-A, tension-anxiety; D-D, depression-dejectioni A-H, anger-hostility; V-A, vigor-activity; F-1, fatigue-inertia: C-8, confusion-bewilderment; TMD, total mood
disturbance.
3.3. Attitudes
A multivariate analysis of variance was conducted to examine
group differences across the four attitude variables: (1 ) satisfaction
with the research experience, (2) feelings toward researchers who
plan and run studies like this, (3) the extent to which the partici-
pants felt that their individual rights were respected while taking
part in the study, and (4) willingness to participate in research of
this kind in the future. Overall, the participant ratings averaged
eight (out of 1 0) or greater for each of the four attitude variables
indicating a high degree of satisfaction with their experience in
the study, positive feelings toward researchers, feeling that their
individual rights had been respected and a high degree ofwilling-
ness to participate in future research of this kind. Significant group
differences were not observed for any of the four attitudes' vari-
ables (Table 3).
3.4. Enrollment, withdrawal from the study, and feelings about
decepdon
Study enrollment, retention of the participants, and withdrawal
of the data were not affected by the authorized deception proce-
dure (Fig. 3). Specifically, none of the prospective participants in
the authorized deception group decided against participating in
the study after learning in the consent form that they would be de-
ceived if they were to participate in the study. Similarly, all pro-
spective participants in the non-authorized deception groups
agreed to participate in the study after reading the informed con-
sent form. No participants from either group withdrew from the
study and none ofthe participants in either group took up our offer
to remove their data from the study after the debriefing process.
At the end of the study, just prior to the debriefing process, the
participants in the authorized deception group were asked how
they felt when they read in the consent form that certain aspects
of the study had been intentionally misdescribed and that this
use of deception was necessary to obtain valid results. Almost all
the participants (90%) reported feeling curious and intrigued upon
hearing that certain aspects of the study had been intentionally
misdescribed. Few subjects reported experiencing negative reac-
tions such as feelings of anxiety (30%), uncertainty ( 1 0%) and anger
(5%). Most participants (85%) reported wondering what parts of the
study had been misdescribed to them.
Chi-squared analysis did not reveal a significant difference in
the proportion of the participants in the authorized deception (9/
20) and non-authorized deception (7/20) groups who wondered
if Aleovcaineru might not be a real drug, y2 (1)=0.42, p=0.52.
The stage of the experiment at which these participants wondered
about the veracity ofthe Alevocaineru is presented in Table 4. Six
participants in the authorized deception group reported wonder-
ing if Alevocaineru might not be a real drug during the actual
experiment; however, these numbers did not differ from those in
the non-authorized deception group where five participants also
reported wondering about the veracity of the Alevocaineru while
the creams were being tested. These results suggest that any sus-
picion about the true nature of the creams was likely not due to
the fact that the authorized deception group had been alerted to
the presence ofdeception in the study.
At the end of the study, following the debriefing, the paragraph
that was included in the consent form for the authorized deception
group, alerting them to the presence of deception in the study, was
read to all participants. The participants in the non-authorized
deception group were asked, "Having participated now, would
you rather have been informed of this?" while the participants in
the authorized deception group were asked, "Having participated
now, would you rather nof have been informed of this?" In the
non-authorized deception group, three participants reported that
they would rather have been informed of the deception at the out-
set of the study and one of these participants stated that she would
be more cautious about future research as a result of her experi-
ence with the deception in this study (Table 5). However, 17 partic-
ipants in the non-authorized deception group reported that they
would not rather have been informed ofthe deception at the outset
of the study. Of these 1 7, 1 0 felt that knowing about the deception
would have made them suspicious, thus biasing their responses
and negatively impacting the outcome of the study, and seven sta-
ted that they did not have a strong preference for one set of
Table 2
POMS between-within ANOVA results with group (authorized deception and non-authorized deception) and time (post-consent and post-debrief).
POMS scile Tiroe I M(SD) Tlrqe 2 M (sD) Time l-time 2 change (within-subjects elTea)
Tension-anxiety
Depression=dejection
Anger-hostility
Vigor-activity
Fatigue-inertia
Confusion-bewilderment
Total mood disturbance
6.03 (3.72)
s.08 (8.79)
3.38 (6.40)
11.7s (5.40)
s.83 (s.02)
s.68 (3.5s)
74.23 (26.30)
4.70 (2.26)
2.4s (s.s6)
r.68 (2.85)
11.7s (8.60)
3.98 (4.0s)
3.8s (2.68)
430 (03s)
F (1, 38) = Z1.sr4, p < 0.001
F(1,38)= 15.86,p<0301
F(1,38)=s.71,P=o.oz
F(1,38)=0.00,p=1.0O:
F(1,38)= 18.88, p< 0.001
F (1, 38) = 31.34, O a 9.001
F (1, 38) = 23.99, t a 6.691
Nofe: "Time I", post-consent; "Time 2", post-debrief; "Time 1" and "Time 2" represent average scores on each scale after collapsing across groups,
Table 3
Means, standard deviations and MANOVA results for attitude variables across the study groups.
Authorized deception M (SD) Non-authorized deception M (SD):- . Between-group diffeiences
Satisfaction with their.research expqrience.
Feelings toward researchers who plan and run studies
like this, involving deception
Extent to which they felt that their individual rights were
respected throughout their participation in the study
Willingness to participate in research of this kind in the future
8.4s (1.00)
8.50 (1.43)
9.6s (0.8r)
9.40 (1.31)
7.85 (r.84)
q.45_u,s4)
e.7o (0.57)
ass (r.3:l
F(1,38)=1.64,P=0;21
F(1,38)=O.1O,p=si5
F(1'38) = g-95, P=632
F (1,38) = 2.76, p = o.1 I
instructions over the other or felt that it was more interesting to
find out at the end.
In contrast, 19 out of 20 participants in the authorized decep-
tion group reported that they would have preferred to be alerted,
as they had been, to the presence of deception in the study. Upon
further questioning, of these 19 participants, 13 expressed a clear
preference to have been alerted to the deception and seven ofthese
13 stated they would have experienced a negative reaction to the
study, such as anger, disappointment, and feeling as though they
had been cheated had they not been wamed about the use of
deception (Table 5). The other six of these 19 participants stated
that they did not have a strong preference for one set of instruc-
tions over the other. The one participant who reported a preference
not to have known about the deception felt that the research find-
Fig. 3. Flow-chart depicting participant recruitment and final enrollment for the
two groups. AD, authorized deception group; non-AD, non-authorized deception
group.
ings would be more accurate if the participants were not warned
about the use of deception.
4. Discussion
The present study sought to investigate an alternate approach
to participant consent in placebo research involving the use of
deception. Authorized deception is designed to alert the partici-
pants to the presence ofdeception in the research, without inform-
ing them about the exact nature ofthe deception [13-15,26]. The
results of the present study show that the magnitude of the pla-
cebo effect did not differ significantly between the participants
who were informed about the presence of deception and those
who were not. While it is possible that some degree of temporal
summation occurred across study trials such that pain increased
with subsequent thermal stimuli [6] this would have occurred in
both study groups and thus should not account for any differences,
or lack thereof, between the authorized deception and the non-
authorized deception groups.
Authorized deception has been proposed as a more ethical ap-
proach to placebo research since it allows the participants the
opportunity to decide whether or not they are willing to volunteer
for a study that involves deception [15]. Although authorized
deception does not replace full informed consent, it is designed
to promote the autonomy of research participants by giving them
a fair opportunity to withdraw from a study knowing that decep-
tion will be involved [14]. Another measure to promote autonomy
in deceptive research is to provide the participants the opportunity
to withdraw their data after having learned the true nature ofthe
study during the debriefing process [14].
The results of the present study do not support the concerns
that authorized deception has adverse effects on key outcome vari-
ables, thus compromising the scientific validity of the data and
introducing bias. Important indicators ofwhether the use ofautho-
rized deception is a viable alternative to the traditional approach of
informed consent (i.e., non-authorized deception) in placebo re-
search of this nature include potential detrimental effects on
recruitment and retention of participants as well as participants'
decisions to withdraw their data following debriefing. The present
results indicate that use of authorized deception did not have a
negative impact on any of these measures; enrollment and reten-
tion of the participants were identical between the two groups
Table 4
Phase of experiment at which participants in each group retrospectively reported
wondering if Alevocainefl was not a real drug,
Phase of experiment
Before coming into the study
While reading the consent form
While completing the questionnaires at the beginning
While the creams were being tested
Now (i.e., when asked)
Total # of subjects
27
10
10
1J
11
97
R"ecruitment
ADN=20
Non-AD N = 20
Posi-Consent
# subjects who declined participaticl
ADN=0
Nr:n-AD N = 0
Post-Debrief
# subjects who elected to remove their data
ADN=0
Non-AD N = 0
Final Enrcrllmenl
ADN=20
Non-Af) N = 20
Note: AD, authorized deception group; non-AD, non-authorized deception group.
Table 5
Comments from participants in the authorized deception and non-authorized deception groups expressing a negative reaction to the use ofdeception.
Group Comments
AD
AD
AD
AD
*l would have been angry if there was deception and you didn't tell me"
..It'sgoodtoknowlabot*thedecepiion|'IfnotIwouldhavebeenaqc!,..lwasinanot}rer:st-udywithdeceptionandt!reydidn'ttell.meand|
'$ would be angry"
"l'm very glad you had that clause in there at the beginning so I could ask my questions and feel okay about participating. I would have wondered whyyou
didn't warn me otherwise"
AD "l would feel cheated ifyou hadn't told me"
AD "[tl would prefer.to know about the deception. It made me feel more comfortable. tf you didn't tell me.l would have felt disappointed and more anxious at
the end, wondering, what else didn't they tell me?"
AD "l would have been disappointed. ifyou hadn't told me"
Non-AD "It's better to know as much as you qal|. I would be more cautious about future researct|. I woutd do it but I d be looking for deception"
and none of the participants in the present study chose to with-
draw their data when given the option to do so after the debriefing
process (Fig. 2).
There is little literature regarding participant decisions to with-
draw data when offered the opportunity [13]. However, the pres-
ent results are in line with at least one other study which
examined the placebo response in relation to asthma in a clinical
population and found none of the 55 patients accepted the offer
to withdraw their data [81. The present findings support the use
of authorized deception and granting participants the option to
withdraw their data as two methods of enhancing the ethical prin-
ciples of placebo research without compromising the scientific
validity and generalizability of the research findings.
The results of the present study also do not support the sugges-
tion that alerting subjects to the use of deception results in in-
creased anxiety t4l. While a few participants reported
experiencing some anxiety upon hearing aspects ofthe study had
been intentionally misdescribed, the vast majority (90%) reported
feeling curious and intrigued. Furthermore, there were no differ-
ences in mood between the two groups (as measured by the POMS
and verbal self-report) following the debriefing when the true nat-
ure ofthe creams and the purpose ofthe study were revealed.
We hypothesized that the non-authorized deception group
would demonstrate a worsening of mood relative to the authorized
deception group following the debriefing since the former group
had not been warned about the use of deception in the study.
We therefore expected these participants to report a negative reac-
tion to the realization that what they thought was an active drug
was actually a placebo. However, contrary to this expectation, both
groups exhibited improvements in mood across the study. These
findings are similarto those of Chung and colleagues [3] who found
reductions in anxiety, frustration and fear after revealing to the
participants the magnitude of their placebo response in relation
to experimentally induced pain.
These improvements in mood may represent an artifact of re-
peat testing or may reflect participants' relief at having completed
the study [3]. Positive interactions with the experimenter through-
out the study may have also contributed to improvements in
mood. One limitation of the present study is the lack of a true base-
line measure of mood prior to the authorized deception interven-
tion. This would have allowed for an assessment of mood
changes resulting from the authorized deception intervention;
however, given that the intervention involved altering the in-
formed consent process and therefore took place before consent
had been obtained, from an ethical standpoint, it was not possible
to obtain a prior baseline assessment of mood,
Another potential concern with the use of authorized deception
is that it may create suspicion in research participants, thus result-
ing in biased data [15]. Although a small proportion of the partic-
ipants in the authorized deception group questioned the true
nature of the AlevocainerM cream, this was no greater than that
ofthe non-authorized deception group, suggesting that any suspi-
cion about the authenticity of the cream was not related to the
authorized deception manipulation. Suspicion, expressed by some
participants, about the authenticity ofthe cream could have been
related to various factors; including, not experiencing a noticeable
reduction in pain when the AlevocainerM cream was applied, or the
fact that the study was advertised as a'Health Psychology'study
and as a primarily undergraduate population, research participants
may have been familiar with psychological research involving
deception [13].
Interestingly, 13 participants in the authorized deception group
expressed a clear preference to be alerted to the presence of decep-
tion in the study compared to only three participants in the non-
authorized deception group. Several explanations may account
for these findings. It is possible that the participants did not have
strong feelings about the use of deception in the research. To the
extent that this is true, it is important to note that this may be spe-
cific to the present population, which consisted predominantly of
healthy undergraduate students who we would not expect to have
a vested interest in the outcome of the study or the efficacy of the
'drug' under investigation.
Other studies have found that the use of deception in psycho-
logical research is not distressing to many subjects [20,21 ]; how-
ever, healthy undergraduate students may have different
attitudes toward being deceived than patients participating in a
clinical trial [9]. The degree to which an individual is troubled by
deception may depend on the extent to which the deceived relies
on the deceiver [26]. As such, the present findings may not gener-
alize to clinical populations who are likely more vulnerable to
deception, often placing considerable faith and trust in clinical
investigators.
It is also possible that the participants in the non-authorized
deception group downplayed the negative effects they experienced
as a result of the deception and thus our findings may not have
accurately captured their true feelings. Participants may, as a
means of 'saving face' [26], minimize the effects of deception or
choose not to report them, particularly when they are asked by
the very experimenter who has just deceived them. This explana-
tion may also account for the finding that more than a third of par-
ticipants in the authorized deception group reported that they
would have experienced a negative reaction had they not been
warned about the use of deception, while none of the participants
in the non-authorized deception group reported actually experi-
encing such a reaction. It is also possible that the prior warning
about the use of deception may have engendered a greater sense
of partnership with and trust in the experimenters, thus allowing
the authorized deception group to more openly share any negative
feelings.
Other data from the authorized deception group also support
the use of the authorized deception methodology in placebo re-
search. Over half the participants in this group reported that they
preferred to be warned about the use of deception at the outset
of the study, prior to agreeing to participate. Numerous partici-
pants expressed gratitude for the openness with which they were
informed of the deception and some participants reported that
they would have likely felt some anger or resentment had they
not been warned (Table 5).
5. Conclusions
Taken together, the results of the present study suggest that
alerting participants to the presence of deception in experimental
pain studies on placebo analgesia does not affect the magnitude
of the placebo effect, recruitment and retention of participants,
nor does it result in any significant psychological harm. Indeed,
the majority of participants who received this form of consent pre-
ferred it to the traditional approach of not alerting participants to
the presence of deception. These findings support the use of autho-
rized deception in laboratory-based studies of placebo analgesia
and suggest that it is a viable and ethically preferable method of
informed consent compared to the traditional approach. Studies
are needed to examine the effect ofauthorized deception in clinical
trials and other placebo research within a clinical setting.
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